Evaluation of a Novel Device for Treatment of Migraine Headache

NACompletedINTERVENTIONAL
Enrollment

296

Participants

Timeline

Start Date

December 17, 2017

Primary Completion Date

November 25, 2018

Study Completion Date

December 25, 2018

Conditions
Migraine Without AuraMigraine With Aura
Interventions
DEVICE

Nerivio Migra-1 active device

"The device is placed on the subject upper arm. when activated, stimulus is applied to influence the subject's perception of a painful stimulus, delivered (or originating) at a different location. Based on diffused noxious inhibitory control mechanism, sometimes referred to as pain inhibits pain principle, conditioned pain modulation evokes an endogenous analgesic mechanism. The modulatory effect is over the whole body, and can be induced anywhere in the body. This approach allows applying the conditioning stimuli away from the painful site."

DEVICE

Nerivio Migra-1 Sham device

The device is placed on the subject upper arm. when activated, the stimulus is applied is not sufficient to influence the subject's perception of a painful stimulus.

Trial Locations (12)

11042

Northwell Health, Inc, New York

14609

Rochester Clinical Research, Rochester

19107

Thomas Jefferson University, Philadelphia

58100

wolfson Medical Center, Holon

63141

Mercy Hospital, St Louis

65810

Clinvest Research, Springfield

89119

Clinical Reseach Consortium, Las Vegas

4428164

Meir Medical Center, Kfar Saba

4941492

Belinson Medical Center, Petah Tikva

06107

Hartford Headache Center, Hartford

Unknown

Rambam Medical Center, Haifa

Souraskyr Medical center - Ichilov, Tel Aviv

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Rambam Health Care Campus

OTHER

collaborator

Northwell Health

OTHER

lead

Theranica

INDUSTRY

NCT03361423 - Evaluation of a Novel Device for Treatment of Migraine Headache | Biotech Hunter | Biotech Hunter